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Executive Summary
Economists have long suggested that to be reliable, a preferred medical care
price index should employ time-varying weights to measure outcomes-
adjusted changes in the price of treating an episode of illness. In this article, we
report on several years of research developing alternative indexes for the treat-
ment of the acute phase of major depression, for the period 1991-1996. The in-
troduction of new treatment technologies in the past two decades suggests
well-known measurement issues may be prominent in constructing such a
price index.
We report on the results of four successively refined methods to measure
price changes. In contrast with Bureau of Labor Statistics (BLS) price indexes,
we find prices decline and productivity increases. In Method 1, we employ a
publicly available retrospective claims database to create BLS-like price in-
dexes for two discrete inputs used in the treatment of depression: antidepres-
sant drugs and physician's services. In Method 2, we move to an episode-based
price index. As a first attempt to adjust for outcome variations, we limit the
analysis to episodes receiving one of seven guideline-level treatments, each of
which have been shown to have equivalent efficacy in clinical trials. In Method
we expand the number of episodes included and allow for finer adjustments
in expected outcomes. We assign expected outcomes to episodes based on an
expert panel's rating of the effectiveness of the treatment received. In Method
our preferred price index, we use hedonic regression to adjust also for
changes in patient characteristics that add to treatment complexity.
We find that our preferred method suggests a decline in the AAGR of treat-
ment for depression of 2.7 percent, which is in contrast to a price increese of 2.6
percent per year when using BLS-like methods. This research suggests con-
structing episode-based, outcomes-adjusted price indexes is a complex and
cumbersome task but an important one for public policy decisions. Although it
may not be sensible or practical for the BLS to produce such an index on a
monthly basis, it is important that policy analysts use episode-based out-116 Busch, Berndt, and Frank
comes-adjusted price indexes when evaluating productivity based on National
Health Accounts.
I.Introduction
Measuring price changes and productivity is important in health care
just as it is in the rest of the economy. More complicated, however, is
the concept of output in the health care sector. For decades, economic
statisticians and health economists have wrestled with various ways of
characterizing output for the purposes of assessing prices and produc-
tivity in health care. Productivity measurement takes on special
significance in the health care sector because various well-known mar-
ket failures preclude one from confidently making normative infer-
ences based on observed market outcomes. Forthisreason,
productivity measurement and the development of price indexes pro-
vide an important source of information on the "value" of health care
services.
Nowhere in the health care sector are the problems of assessing the
value of treatments and productivity of spending more challenging
than in the case of treatments for mental disorders. Questions about the
effectiveness of treatments and welfare losses from moral hazard in in-
surance have long created concern that the value of spending on men-
tal health may be low relative to other health services. Because mental
disorders are often chronic, recurring conditions, mortality is not typi-
cally an appropriate outcome measure. Thus, defining outcomes often
relies on more subjective and difficult to measure constructs. Creating
price indexes that account for the changing quality and effectiveness of
mental health treatments therefore poses important measurement
issues.
For some time, health economists have posited that an appropriate
price index is one based on episodes of treatment of selected illnesses
and conditions, incorporating technological and institutional innova-
tions that change the mix of inputs used to treat the condition, and in-
cluding any effects on changed medical outcomes. Scitovsky (1967)
illustrated one approach to implementing an episodes-based analysis
of prices by examining the changing cost of treating episodes of six spe-
cific illnesses. The research line described below builds on the tradition
begun by Scitovsky and applies it to the most prevalent and costly of
the mental disorders, major depression. In this article, we report on
several years of research focused on developing price indexes for the
treatment of depression.Measuring Productivity in Mental Health Care 117
Several features of treatment for depression raise well-known meas-
urement issues that may be prominent in constructing such a price in-
dex. In the past two decades, new technologies have been introduced
indicating the potential for changes in outcomes of treatment. Treat-
ment patterns have shifted within treatment classes (e.g., from older to
more recently developed drugs) and between treatment classes (e.g.,
from psychotherapy to drug treatments). Fundamental organizational
changes may also have affected prices and treatment choice.
We begin by describing the methods used by the BLS to construct
official health-related Producer Price Indexes (PPIs). We then describe
four methods for constructing a supply price index for treatment of de-
pression. In Method I, we mimic the procedures used by the BLS but
employ prices and quantities from a publicly available private insur-
ance claims database. We also deviate from BLS procedures by using
the claims data in conjunction with index number formulas not cur-
rently used by the BLS. In the three subsequent methods, we take an
episode of illness approach, pricing treatment for a specific illness epi-
sode rather than discrete inputs. Method 2 aims to hold outcome con-
stant by limiting the price index to episodes of treatment that meet a
common outcome standard, as determined by the outcomes of patients
assigned these treatments in clinical trials. Method 3 incorporates vari-
ation in expected clinical outcomes by assigning expected outcomes to
treatments based on ratings of treatments by a panel of experts.
Method 4 uses the same methods as 3, but adds a regression analysis,
allowing us to adjust prices for varying patient characteristics that may
complicate treatment.
In our first analysis, we apply BLS methods to claims data. The re-
sults based on the BLS methods allow us to determine whether our re-
sults obtained using alternative methods, such as the "episodes"
approach, are due to differences in data or differences in the methods.
Unlike the data collected by the BLS, the data we employ is from a
nonrepresentative sample of privately insured individuals with exten-
sive health insurance coverage. In addition, these data include transac-
tions rather than list prices. This distinction may be important if
organizational changes in health insurance during the time period con-
sidered have resulted in the negotiation of larger discounts, thus in-
creasing the difference between transaction and list prices over time.
For Methods 2, 3, and 4, we move from pricing discrete inputs to
pricing an episode of treatment. We use health plan enrollment infor-
mation, diagnoses and dates contained in the retrospective claims
data to combine claims such that they reflect episodes of outpatient118 Busch, Berndt, and Frank
treatment for major depression. These treatment episodes consist of cli-
nician visits of various types, pharmaceuticals, or combinations of
these inputs. Information on outcomes is not recorded in administra-
tive data, which necessitates a second source for outcome information.
Based on a review of the clinical literature and published treatment
guidelines, we identify in Method 2 all episodes treated with proven
efficacious treatments. To increase the validity of this method, we make
considerable efforts to match closely the treatments reflected in the
data to treatments evaluated in clinical trials.
By limiting the price index to episodes treated with guideline-level
treatment, we omit about 50 percent of the observed episodes from the
price index. We also implicitly assume that all guideline-level treat-
ments produce similar clinical benefits, an unlikely prospect. Descrip-
tive results indicate an increase over time in the share of episodes
treated with guideline-level treatment between 1991 and 1996 (from 35
to 55 percent). A real source of productivity increase is thereby over-
looked by applying Method 2. In Method 3, we allow outcomes to vary
by treatment and patient type. Allowing this variation increases the
number of episodes included in the price index. We expand the use of
information on outcomes by convening a panel of experts, who were
asked to estimate the expected outcomes of treatments reported in the
data. These ratings estimates were then combined with price and quan-
tity data to construct price indexes that take into account expected
outcomes.
In Method 4, we maintain the same outcome measurement approach
and episode construction as in Method 3, but we recognize that the pa-
tient population may have been changing over time. Method 4 uses
hedonic regressions to adjust for demographic shifts and the changing
complexity of treated cases. This adjustment is accomplished by mea-
suring the presence of co-occurring medical and psychiatric conditions
that complicate care and tend to diminish responses to treatment.
The procedures and data underlying Methods I through 4 are sum-
marized in table 5.1. In contrast with official price indexes, the price in-
dexes we construct suggest real price declines, although the magnitude
varies across methods. We focus on what has been learned about con-
structing a preferred medical care price index both generally and spe-
cifically for the treatment of depression.
In the next section, we discuss major depression and its treatment.
Section III describes the data used in the analyses. Section IV discusses
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scribes Method 1. Section VI describes the construction of episodesand
the procedures used in Method 2 to assign outcomes basedon clinical
trial results. The quantities and prices of guideline-leveltreatment bun-
dles are also described. Section VII describes Method 3 and theelicita-
tion methods used to gather data on outcomes froman expert panel,
and incorporates these outcomes into a price index. In Section VIII,we
incorporate changes in the characteristics of the patients used in the
calculation of the Method 4 price indexes. In Section IX,we consider
the episodes-based price indexes in the context of officialprice indexes,
decompose the discrepancies, and interpret them. SectionX presents a
conclusion.
II.Depression
Epidemiological research indicates that in the early 1990s, 10.3percent
of the U.S. population met the criteria for major depressionat some
time during a twelve-month period.1 Depression is often accompanied
by health problems. They include anxiety, eating disorders,substance
abuse, and other medical conditions.2 Although thereasons are still not
well understood, womenparticularlywomen under age 25are
much more likely to suffer from depression thanare men; the relative
lifetime female/male prevalence rate is about 1.7. Rates ofrecurrence
for major depression appear to beno different for women and men.3
Several studies have shown that depression has similaror greater func-
tional impairments than those attributed to other episodicand chronic
medical illnesses.
Several new treatments for depression have been introducedin the
past two decades. In the area of psychotherapy, variousnew tech-
niques have expanded treatment options, including interpersonalpsy-
chotherapy (IPT), family therapy, and cognitive behavioraltherapy
(CBT). In addition, extraordinary advances have beenachieved in the
area of antidepressant medication. Antidepressant medication has
three general classes: tricyclic antidepressants (TCAs); selectiveseroto-
nmreuptake inhibitors (SSRIs), which include brand-name drugssuch
as Prozac, Zoloft, and Paxil; and monoamine inhibitors (MAOIs),
which, due to side effects and dangerous interactions,are generally
used only for cases that are resistant to other forms oftreatment. The
newer SSRIs offer some distinct advantages over older TCAs. SSRJsare
associated with lower risk of overdose and fewer and lower levels ofMeasuring Productivity in Mental Health Care 121
several side effects. The advantages of SSRIs come at a significantly
higher pecuniary cost than most TCAs.
A review of approximately thirty major clinical trials and meta-
analyses from the clinical literature on comparative efficacy of acute
phase treatments points to several key conclusions.4 First, psycho-
therapies of all kinds have been shown to result in superior outcomes
compared to no treatment. When compared amongst themselves, the
different forms of psychotherapy appear to have no significant differ-
ences in outcomes.5 Second, for less severe formsof depression,
psychotherapies alone, TCAs with medical management, and SSRIs
with medical management appear to produce comparable outcomes.
Each of these therapies produce significantly better outcomes than pla-
cebo treatments. Combination treatments with these therapies as com-
ponents also generate equivalent levels of efficacy for less severe forms
of depression.
Third, for more severe forms of depression, the bulk of the evidence
suggests that TCAs alone, SSRIs alone, and combinations of drugs and
psychotherapy have comparable levels of efficacy and that each results
in superior outcomes compared to psychotherapy alone. Recently
some evidence has emerged showing some extra improvementfrom
the combination treatments relative to medication alone,6 particularly
for more chronic forms of depression.7
III.Data
In all cases, approaches to price index construction are compared using
quantities and prices of outpatient treatment for depression based on
retrospective claims data from the publicly availableMarketScanTM da-
tabase. These data consist of 1991-1996 medical claims from four large
self-insured employers that offered more than twenty-five health plans
to 428,000 employees and their dependents. The data consist of enroll-
ment, inpatient, outpatient, and pharmaceutical claims. This data may
not be representative of the prices paid or treatment provided by other
purchasers such as individuals, government, or small employers,
thereby limiting the generalizability of some of our findings. For exam-
ple, the health benefits offered to enrollees in this database are quite
generous relative to the general market for privatehealth insurance in
the United States. Individuals insured by private payers may be health-
ier than the general population, suggesting less complicated treatment122 Busch, Berndt, and Frank
plans. Large employers may have the market power to negotiate sub-
stantial price discounts, reducing prices compared with the average
purchaser.
IV.BLS Procedures
Although the Consumer Price Index (CPI) is generally the most widely
reported measure of changes in general prices, in this article we focus
on comparisons with Producer Price Indexes (PPIs). Medical-related
CPIs limit their scope to consumers' out-of-pocket payments and that
portion of third-party insurance paid for out-of-pocket by employees.
Employers' contributions to employee health insurance are excluded,
as are all medical payments to providers by governments. Thus, al-
though national health spending in the mid-1990s constituted about 14
percent of GDP, the total weight given medical care items in the CPI
was only about 5 percent.8 These limits on the definition of "consumer
price" cloud the interpretation of the CPI for health care. Unlike the
CPI, medical PPIs measure average changes in selling prices received
by domestic producers for their output and include revenues from
Medicare, Medicaid, and other private sources (such as third-party
payment and direct patient cash payments), making the PPI a more
reasonable comparison for examining changes in medical care prices.
For quite some time, the BLS has published PPIs for certain medi-
cal-related manufacturing industries, such as pharmaceuticals and di-
agnostic equipment. Only relatively recently, however, has the BLS
begun publishing PPIs for medical service industries such as hospital
and physician services. The BLS initiated a PPI for an aggregate of
health care services in 1994, for offices and clinics of doctors of medi-
cine in 1993, and for hospitals in 1992. These PPIs encompass various
more detailed industries. For example, offices and clinics of doctors of
medicine includes physician services from psychiatrists, general/
family practitioners, and internists. Hospitals includes hospitalser-
vices from general medical and surgical hospitals, psychiatric hospi-
tals, and specialty non-psychiatric hospitals. Select PPIs relevant to
mental health care are listed in table 5.2. These medical care PPIs indi-
cate price increases ranging from 2.2 percent to 6.1 percent per year in
the early to mid-1990s. Of the medical PPIs published by the BLS, the
two that are most relevant to outpatient care for the acute phase of ma-
jor depression are psychotherapeutic drugs and physician services
(offices of doctors). While we focus here on these two PPIs, many of theMeasuring Productivity in Mental Health Care 123
Table 5.2
Mental health related BLS Producer Price Indexes
Producer category 1991 1992 1993 1994 1995 1996 AAGR
Office of doctors 100 102.8105.9 107.8 +0.025
Psychiatrists, small 100 102.9104.7 106.8 +0.022
group/solo
All outpatient 100 102.4106.9 114.2+0.045
services
Psychiatric hospital 100 103.3 113.0119.4+0.061
outpatient services
Psychotherapeuticsboa 107.6 113.4 116.2 120.4 120.5+0.038
alndex normalized to 1991 base year.
Source: U.S. Bureau of Labor Statistics, Producer Price Indexes.
conceptual and empirical issues discussed are common to other Pro-
ducer Price Indexes.
Pricing the output of prescription pharmaceuticals presents some
particularly interesting issues involving treatment of generic drugs and
of quality improvements in new products that are beyond the scope of
this article.9 For our purposes, it is important to note that to construct
pharmaceutical PPIs, the BLS chooses a sample of drugs that is then re-
priced each month. With respect to physician services, the BLS con-
structs a national sample of physician practice units from which a
random bill is chosen. From this bill, the BLS calculates the net price
paid to the practice for the entire set of services and procedures pro-
vided during a single office visit, distinguished by payer type. The
physician's output from this visit is represented by the content of the
patient's bill, including specific procedure (CPT-4) codes associated
with that visit, and is related to a particular ICD-9 diagnosis. Given this
sample bill, the BLS contacts the physician practice unit each month
and asks it to reprice what the current net transactions prices would be
for that particular fixed bundle/payer of services. Hence, the unit of
analysis or industry output is the group of procedures delivered dur-
ing the randomly selected single office visit.
It is worth noting that, given these definitions of industry output and
the BLS' use of fixed itemized components for obtaining price quotes,
major input substitution of treatment for a condition (such as the
changing mix of outpatient and inpatient care or, in the case of outpa-
tient care for major depression, psychotherapy and psychotherapeutic124 Busch, Berndt, and Frank
drugs) is not captured. Such a zero-substitutability definition of medi-
cal outputs leads to the existence of a substitution bias.
Although the BLS seeks transactions rather than list prices for its
price quotes, the agency is aware that compliance by firms is easier
with list than with actual transaction prices. The BLS currently drawsa
sample of items for each industry on average about every seven years
and then reprices this fixed set of items monthly until an entirely new
sample is drawn. In recognition of the fact that seven-year time lags
could yield a sample of products and services unrepresentative of cur-
rent market transactions, the BLS announced in 1995 that samples
would be supplemented at one- or two-year intervals for certain tech-
nologically dynamic industries, including pharmaceuticals. PPIs are
then constructed using a modified fixed weight Laspeyres price index
formula over the individual price quotes.
Finally, these BLS price index procedures do not take into account
any variations across therapies and over time in expected outcomes
from treatment. Further discussion of the BLS' procedures for measur-
ing prices in the health care industries is given in Berndt, Cutler, Frank
et al. (2000b).
V.Method 1: An Index That Mimics the BLS
To distinguish differences arising from the methods used to construct
the price index from differences due to data, we construct a price index
that mimics the BLS' methods but uses as inputs price and quantity
data from the MarketScan data. As discussed above, MarketScan data
differs from data collected by BLS because patients are froma
nonrepresentative subset of the population, transaction rather than list
prices are recorded, and prices for all outpatient services and
pharmaceuticals are utilized instead of those from a random sample.
We initially focus on PPIs for two discrete inputs commonly used in the
treatment of major depression: psychotherapeutic drugs and physician
services.
Psychotherapeutic pharmaceuticals used in the treatment of depres-
sion are identified from national drug codes (NDC) reported on phar-
maceutical claims. For a claim to be included, the drug had to be
FDA-approved for the treatment of depression and had to be linked
with a depression diagnosis (ICD-9 codes 296.2 and 296.3). Fourteen
distinct molecules were identified.
Physician services for the treatment of depression were identified by
procedure codes (CPT-4) attached to a major depression diagnosis inMeasuring Productivity in Mental Health Care 125
the outpatient claims of the MarketScan data.1° In all years, the most
common procedure was a fifty-minute psychotherapy visit. Other pro-
cedures included lab tests, psychiatric diagnostic testing, general office
visits, and medical management visits.
Following BLS methods, the fixed quantity weight Laspeyres price
index formula was used to aggregate prices and quantities. Various
other price indexes can be computed, each having implicit assump-
tions on the extent of ex-ante substitutability among the alternative
treatment bundles. Because alternative index number formulas and
underlying assumptions are well known in the literature,11 and since in
our research we found choice of formula not to affect price change
greatly, we present only two price indexes here: a fixed weight
Laspeyres and a Fisher-ideal index. The Fisher-ideal index is a geomet-
ric mean of the fixed-weight Laspeyres and fixed-weight Paasche in-
dexes, where the latter is analogous to the Laspeyres except that it
employs current period quantities rather than base period quantities as
fixed weights.
For both the Laspeyres and Fisher-ideal price indexes, we construct
an aggregate price index for antidepressant drugs and for physicians'
services using the Medstat MarketScanTM data. The top row of tables
5.3 and 5.4 presents the BLS-type antidepressant price indexes, while
that for physicians' services is given in the second row of tables 5.3 and
5.4. For antidepressant drugs, both the fixed weight Laspeyres and
Fisher-ideal index rise at an average annual growth rate (AAGR) of 4.1
percent, slightly greater than the 3.8 percent in the BLS' PPI for psycho-
therapeutic drugs. Hence, for antidepressant drugs, there is relatively
little difference in the BLS' index and that based on the Medstat data.
With respect to physicians' services, as seen in the second row of ta-
ble 5.3, the Laspeyres index based on Medstat data has an AAGR of 2.5
percent, a rate identical to that for the BLS' PPI for office of doctors (ta-
ble 5.2). When one employs instead the Fisher-ideal price index, the
physician service price index grows less rapidly, at 1.8 percent per year.
This lower growth rate could reflect the increasing role over time of
general/family practitioners and internists in treating depression and
the reduced role of psychiatrists, a treatment shift not captured by the
fixed weight Laspeyres index.
In summary the AAGRs of price indexes based on the fixed weight
Laspeyres index, using Medstat data, are very similar to the BLS' PPIs
for antidepressant drugs and for physicians' services, based on their
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VI.Method 2: Treatment Episodes
Next, we construct price indexes that represent a significant conceptual
shift from traditional medical care price indexes. Price indexes that
measure the price of discrete inputs, such as those in Method 1, may
fail to capture changes in treatment choice that affect productivity In
the approach to price measurement described next, which we refer to
as Methods 2a and 2b, we move from pricing inputs in isolation to pric-
ing an episode of treatment.12 We do this in recognition that a course of
treatment more closely reflects the good consumers expect to purchase
through medical carealleviation of disease. We aggregate outpatient
and pharmaceutical claims such that combinations of inputs reflect the
treatment received by an individual patient. Methods 2a and 2b differ
in the algorithm used to construct episodes. Using the episode as the
unit of analysis, we aggregate prices and quantities to form price in-
dexes for "the acute phase of treatment for major depression."
Constructing Episodes of Treatment
To implement a price index for treatment episodes, individual claims
are combined using patient identifiers, diagnostic information, and
dates to represent episodes of treatment. For depression, a chronic dis-
ease, defining an acute episode required extensive knowledge of the
disease, its course, and the administering of treatments in practice. At
several key points, we benefited from consultations with clinicians
about these issues.13 Their input was crucial to developing this ap-
proach. We also found the idiosyncrasies of claims data caused addi-
tional complexities. To illustrate these difficulties, we describe results
from our initial attempt at implementing the episode concept (Method
what we learned, how we improved on these methods (Method
and the changes in the price index resulting from these seemingly
minor improvements. While not changing the qualitative findings, the
magnitude of our results are affected. In each case, we find declines in
real prices, but Method 2b suggested less rapid declines than we origi-
nally reported (Method 2a).
We identify all ambulatory claims associated with either single or re-
current episodes of depression, as defined by the ICD-9 primary diag-
nostic codes 296.2x or 296.3x.14 We choose these specific diagnosis
codes for three reasons. First, clinical trials typically use these defi-
nitions as their entry criteria. Because we assign outcomes based on
clinical trial results, we want the patients in our data to have symptomsMeasuring Productivity in Mental Health Care 129
similar to those patients chosen for clinical trials. Second, chart reviews
indicate that the specificity of these two diagnoses is high, i.e., the pro-
portion of true positives is high, while the proportion of false positives
is very low. Third, clinicians could employ a more ambiguous diagno-
sis such as "depression not elsewhere classified" or "neurotic depres-
sion." The fact that clinicians designated the diagnosis as either 296.2
or 296.3, rather than codes corresponding to more ambiguous diagno-
ses, indicates a conscious act of volition.
Since we do not directly observe symptoms in retrospective claims
data, our claims-based definition of an episode of treatment does not
correspond directly to an episode of the illness.15 When claims data in-
dicate that psychotherapeutic drugs were prescribed, we consider the
number of days of treatment provided by the prescription as the time
period over which an individual received care. We follow American
Psychiatric Association (1993) guidelines in defining an episode of de-
pression as new if a diagnosis is preceded by a period of at least eight
weeks of not meeting clinical criteria for depression.16 Thus, we use an
eight-week period without treatment to define new treatment epi-
sodes. We eliminate episodes for which we do not observe the entire
episode due to censoring; all episodes for which we do not observe
eight weeks both pre- and post-episode are excluded.
We next exclude all depressive episodes involving inpatient (hospi-
tal) claims. Patients with only outpatient care constitute the vast major-
ity of treatment episodes (75 to 80 percent). We exclude patients with
psychiatric hospitalizations for several reasons. First, inpatient claims
data typically do not contain information on the drugs prescribed for
treatment; thus, characterizations of inpatient care are inherently in-
complete.'7 Second, because of other incomplete information regarding
illness severity and comorbid conditions, it is difficult to use adminis-
trative claims data to characterize fully an illness diagnosis and there-
fore to make judgments about the appropriate use of hospital services
for treating major depression. Third, few clinical trials specifically ad-
dress inpatient treatment for major depression, making it difficult for
us to assign outcomes to treatments. Finally, because there was consid-
erable evidence of overuse of hospital services in the aggregate during
the late 1980s and early 1990s, the inclusion of hospital services in our
1991 base year could make interpretation of price changes trouble-
some.18
Our strategy of limiting severe cases by excluding individuals hospi-
talized for treatment of depression is likely to be only partly successful.
During the 1990s, there has been a substantial reduction in inpatient130 Busch, Berndt, and Frank
psychiatric admissions and in the length of stay for hospitalized cases.
An implication of this trend is that the population of people treated
only on an outpatient basis may, on average, be suffering from more se-
vere forms of depression over time.
Using information on procedures (e.g., type of visit, whether drug
prescribed) as given by the CPT-4 codes, we describe the composition
of treatment that occurred within a treatment episode. Drug treatment
is based on the national drug codes (NDC) reported on the claim. The
NDC classification revealed use of seven TCAs, three SSRIs, two other
serotonin-related drugs,19 three MAO inhibitors, four anxiolytics, and
four heterocyclics for treatment of depression. Direct medical spending
for such treatment episode was calculated using actual transaction
data. All payments made by the insurer to the provider and any cost-
sharing assigned to the patient (e.g., patient out-of-pocket copayment
for prescription drugs) were summed to a nominal dollar total for each
treatment episode.
Assigning Expected Outcome
The results from our review of the clinical trial literature enabled us to
develop a set of treatment "bundles" that group therapies into what we
envision as therapeutically similar groups for treatment of a specific
form of major depression. This identification of treatment bundles that
result in similar expected health outcomes is a crucial step in the con-
struction of medical treatment price indexes that employs results from
clinical trials to account for expected outcomes. The implicit assump-
tion in this methodology is that obtaining therapeutically similar out-
comes from alternative treatments provides a useful approximation to
achieving similar expected utility levels. We recognize this is only an
approximation. This is particularly true for depression, where the con-
stellation of side effects across treatment can vary significantly and
idiosyncratically, and can lead to differential patient compliance and
patient preferences between the SSRIs and TCAs.2°
It is important to note here that our use of guideline standards of care
in Method 2 imposes a rather unrealistic shape to the production func-
tion for treatment of depression. It takes on a step function form. For
example, if one were to receive six psychotherapy visits for treatment
of depression, our analysis would treat the case as "effective," whereas
four or five visits would be viewed as "ineffective." This is unlikely to
provide an accurate representation of clinical reality Nevertheless, if
we limit ourselves to results from the clinical literature, we have littleMeasuring Productivity in Mental Health Care 131
systematic analysis upon which to make alternative assumptions.
Thus, we use the step function production model as a point of depar-
ture. In Methods 3 and 4 we relax this assumption.
In Method 2a, we identify five major classes of treatments that have
been proven effective in the treatment of depression:
Psychotherapy alone, 6-15 visits;
Short-term TCA treatment (31-180 days) alone or with medical
management;
Short-term SSRI treatment (31-180 days) alone or with medical
management;
Short-term TCA treatment (31-180 days) with some psychotherapy;
Short-term SSRI treatment (31-180 days) with some psychotherapy.
Method 2a also employs restrictive inclusion criteria, only considering
episodes containing these precise number of visits; for example, epi-
sodes with more than fifteen psychotherapy visits are excluded.
Initial empirical analyses suggested several possible improvements
to our method of episode construction and censoring. Method 2b incor-
porates such changes to the data underlying construction of the price
indexes. Procedure codes were missing for many outpatient claims. We
developed an algorithm to identify missing psychotherapy procedure
codes and reconstructed episodes of treatment including these codes.
In recognition that in actual practice it is common to switch or augment
drug therapies, two treatment categories were added to the five in
Method 2a: short-term combined TCA/SSRI treatment, 31-180 days,
both alone and in combination with psychotherapy. We also include
episodes that involved longer treatment or those extending beyond
fifteen visits or six months but count only visits and drugs occurring in
the first six months of care. Finally, we improve our definition of cen-
soring, limiting our analysis to the first six months of treatment. Be-
cause we believe these procedures represent improvements over
Method 2a, we focus our discussion on the results obtained using
Method 2b, although we illustrate sensitivity by comparing results
from Methods 2a and 2b.
Results
The quantity sharesofthe seven treatment bundles derived
under Method 2b, by year, are presented in table 5.5. Several not-
able trends appear. First, there has been a very substantial decline in132 Busch, Berndt, and Frank
Table 5.5
Guideline-compatible treatment bundle quantity proportions post revisions to episode
construction, by year
psychotherapy-alone treatments, from 41 percent in 1991 to 22 percent
in 1994, and then up slightly to nearly 28 percent in 1995. Second, for
the medication-only treatments, SSRI alone has grown from 10 to 13
percent, even as TCA alone declined from 6 to 2 percent; the sum of the
two medication-only treatments has remained relatively constant, at 15
to 16 percent. Third, most of the compositional change among treat-
ment bundles has involved the medication-psychotherapy combina-
tion treatments. While the TCA/psychotherapy combination fell from
12 to 4 percent between 1991 and 1995, the SSRI/psychotherapy treat-
ment share doubled, from 24 to 48 percent of all treatments. By 1995,
the SSRI/psychotherapy combination had become the modal treat-
ment bundle.
With the prices and quantities of the revised seven treatment bun-
dles as elementary building blocks in Method 2b, we construct aggre-
gate price indexes. Again, we found choice of formula did not greatly
effect aggregate measured price change and therefore present only two
price indexes: the fixed weight Laspeyres and the Fisher-Ideal index.
The results are presented in the second panel of table 5.3 (Laspeyres)
and table 5.4 (Fisher-Ideal).
The most striking result that immediately emerges from table 5.3 is
that, over the 1991-1995 time period, the aggregate measure of price
change for treatment of depression is affected substantially by the vari-
ations in inclusion/exclusion criteria between Methods 2a and 2b. With
the more restrictive inclusion criteria of Method 2a, the AAGR from
1991 to 1995 is 9.1 percent, whereas in Method 2b, when the greater
Treatment 19911992199319941995Overall
Psychotherapy alone 41%33%24%22%28% 28%
TCAalone 6 5 3 3 2 4
SSRI alone 10 12 14 15 13 13
Psychotherapy and TCA 12 12 10 5 4 8
Psychotherapy and SSRI 24 31 39 46 48 40
TCA/SSRI 2 2 2 2 <1 2
Psychotherapy and TCA/SSRI 5 6 9 7 4 7
Sum of guideline-compatible episodes522 93913531391 834 5039
Total episodes 1479221124262468148310,067
Percent guideline-compatible 35%43%56%56%56% 50%Measuring Productivity in Mental Health Care 133
number of treatment bundles and longer treatment cases are included,
the 1991-1995 AAGR is but -0.6 percent. As seen in table 5.4 for the
Fisher-Ideal indexes, the AAGRs are -8.5 percent (Method 2a) and
-0.7 percent (Method 2b).
With the preferable Method 2b procedures, the treatment price index
for acute phase major depression has hardly changed, remaining at 100
or falling slightly to around 97. These price indexes reveal an increase
from 1991 to 1992, a fall in 1993, a fall again in 1994, then an increase in
1995. Differences between the fixed-weight and Fisher-Ideal indexes
are relatively minor.
By comparison, over the 1991-1995 time period, the aggregate PPI
for all finished goods increased about 5 percent and that for antidepres-
sant prescription drugs increased by about 20 percent. From 1992 to
1995, the PPI for psychiatric hospital services increased by about 10
percent, while between 1994 and 1995 the overall health services PPI
increased 2.4 percent. Thus, while our price indexes for the treatment
of acute phase depression are either flat or very slightly falling, they all
grow considerably less than the various official "discrete input" PPIs.
Critique of Method 2
These Method 2 price indexes represent a first approximation of an
outcome-adjusted treatment episode price index. While the use of pub-
lished treatment guidelines as a proxy measure for quality of care and
expected outcomes may be preferable to ignoring outcome variations
altogether, it nevertheless imposes a strong restriction on the shape of
the medical treatment production function. Specifically, use of the
guideline criterion implies that simply by observing input quantity
combinations, one can assign each observed treatment episode either a
zero (not compatible, not effective) or a one (guideline compatible, sat-
isfactory outcome, and equal across all guideline compatible treat-
ments)a single-step production function. Use of the step function
production relationship is very simplistic and does not make use of a
great deal of clinical and medical information that is now known.
Moreover, by limiting the price index to those episodes meeting guide-
line treatment standards, we ignore 50 percent of delivered care. We
find that the share of episodes treated with guideline-level care is in-
creasing from 35 to 55 percent from 1991 to 1995. Suggested causes of
this increase include the dissemination of practice guidelines, ex-
panded treatment choice and organizational changespotentially real
productivity gains not captured by Method 2.134 Busch, Berndt, and Frank
VII.Method 3
Method 3 incorporates procedures that allow us to approximate more
closely the effectiveness of treatments in a naturalistic setting and to
recognize the variation in expected outcomes of guideline-level treat-
ments once clinical practice deviates from the pristine world of clinical
trials. We convened a panel of clinicians and researchers, provided
them with detailed summaries of the clinical literature, and elicited
outcomes for a wide range of treatment types and quantities. We as-
signed outcomes to treatment episodes based on the ratings and treat-
ment/patient type. This allowed us to infer outcome information for
episodes whose treatments do not reach the level or type recom-
mended by guidelines and to capture variation over time in the pro-
portion of treatments "off-frontier."21 By integrating knowledge
concerning the efficacy and effectiveness of alternative treatments
based on micro clinical trial data with the judgments of clinical experts,
the Method 3 price indexes better capture the effects of changing treat-
ment practice.
First we classified each episode of care previously constructed from
the MarketScan data along two dimensions: type of patient and type of
treatment. An example of a patient/treatment cell is women between
ages 18 to 45, with no medical comorbid conditions and no recent sub-
stance abuse problems, treated with an SSRI for at least thirty days plus
three or more psychotherapy visits in a specialty mental health setting.
Based on these dimensions, we identified about 200 patient-treat-
ment cells. To reduce the burden of the expert panel's deliberations, we
eliminated most of the treatment/patient cells having fewer than thirty
patients over the six years. This reduction resulted in 120 treat-
ment/patient cells covering 9,054 episodes (67 percent of ambulatory
treatment episodes). Although 867 patient visits involved an ICD-9 de-
pression diagnosis, their medical claims contained no information on
any mental health treatment (n = 816) or there were no expenditures
(n = 51). When these "no treatment" episodes are deleted, the number
of remaining episodes dropped to 8,187. The number of rated treat-
ment cells for the treatment bundles is given in the first column of table
5.6. We now discuss the Method 3 procedures in greater detail.
Outcomes Assessment: The Expert Panel
To obtain expected outcome probability assessments for each of the 120
treatment/patient cells, we combined research data on clinical efficacyMeasuring Productivity in Mental Health Care 135
Table 5.6





of patient(%) of of full spendingfull
Treatment strata episodesremissionper episoderemission
1 brief office visit 11 901 (10)0.17 $53 $ 2618
2 brief office visits 1 42 (0) 0.15 95
3 or more brief office
visits
1 34 (0) 0.20 235 4700
1 psychotherapy visit9 978 (11)0.16 136 13573
2-3 psychotherapy
visits
8 816 (9) 0.19 278 6930
4-9psychotherapy
visits
9 1292(14)0.25 558 5577
10-24 psychotherapy
visits
9 637 (7) 0.34 1055 5553
TCA 30 days and
1-3 psychotherapy
visits




2 49 (1) 0.24 856 9507
TCA >30 days and
No psychotherapy2 30 (0) 0.20 280 5585





2 63 (1) 0.35 864 4320
SSRI30 days and
No psychotherapy2 65 (1) 0.20 173 3447
1-3 psychotherapy














1 19 (0) 0.20 756 15116aMedian probability of being depression-free was 0.18 but was set to the minimum value
of 0.15 for calculating incremental spending.
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Table 5.6 (continued)




of patient (%) of of full spendingfull
Treatment strata episodesremission per episode remission
SSRI>30 days and
No psychotherapy 11 552 (6)0.28 $ 308 $2367
1-3 psychotherapy
visits




9 801 (9)0.35 1050 5249
No psychotherapy,
some anxiolytics
1 20 (0)0.32 315 1853
1-3 psychotherapy
visits, some anxiolytics












1 39 (0)0.28 557 4284
Lithium alone 1 20 (0)0.20 538 10753
Lithium plus
antidepressants
2 67 (0)0.26 820 7454
Antipsychotics alone 1 15 (0)0.15 476
Unspecified mental health
treatment




Total 120 9054 0.23 473 5909Measuring Productivity in Mental Health Care 137
and effectiveness with expert clinical opinion.23 We asked ten clinicians
to rate outcomes from these treatments in terms of changes in the Ham-
ilton Depression Rating Scale (HDRS). The elicitation process consisted
of three distinct stages. In the first stage, a psychiatrist provided a sum-
mary of published results of treatment efficacy and effectiveness for
each of the treatment/patient cells. In the second stage, an elicitation of
outcome distributions was conducted by mail for each of the 120 treat-
ment/patient cells.24 Finally, a face-to-face panel meeting was con-
vened in January 1999, and each expert was asked to rate again those
cells having a substantial disagreement among experts. For our pur-
poses, the relevant outcome was the share of patients depression-free
as measured by the HDRS after sixteen weeks of treatment. Panel con-
sensus emerged at the end of the panel meeting.
The weighted average of the median outcome results from the expert
panel elicitation process for each treatment (averaged over patient
type) and average spending from the MarketScan data are reported in
columns 3 and 4, respectively, of table 5.6.25 The ratings indicate sub-
stantial variation in several of the treatments previously assumed in
Method 2 to have equivalent efficacy. The average expected outcome
rating of these guideline-level treatments ranged from 20 (TCA alone)
to 35 percent (psychotherapy plus SSRIs). This range suggests that the
quality effect of changes in treatments over time, as indicated in table
5.5, may affect the price index. Moreover, similar to results in clinical
trials, the ratings indicate that clinicians believe 15 out of 100 patients
will spontaneously remit, even in the absence of recognized treatments
for depression.
In implementing an outcome-adjusted price index, the relevant
outcome increment is the likelihood of symptom reduction relative to
the "waiting list" or "no treatment" outcome. Therefore, we incorpo-
rate the fact that the no-treatment option ("watchful waiting" or "wait-
ing list") frequently results in spontaneous remission of depressive
symptoms and focus on the incremental gains in outcome obtained
from treatment over and above waiting list. Reported in the final
column of table 5.6 is the average incremental spending per full
remission.
To gauge the effect of incorporating more refined outcome adjust-
ments, we construct two distinct series of price indexes. First, we con-
struct price indexes similar to those in Method 2b but increase the
number of episodes used to construct the price index by including all
patient/treatment cells rated by the panel. This change increases the138 Busch, Berndt, and Frank
share of episodes included in price index calculations by 40 percent
(from 50 to 70 percent of all episodes). Because measures of outcome
variation are not incorporated, all cells rated by the panel are treated as
having equivalent outcome.
In the preferred Method 3 price index, we combine the ratings of the
expert panel's outcome assessments with changes over time in the
shares of observed treatment modalities (and their costs). Thus, this
price index measures changes in the price per incremental remission.
Once again, we limit our discussion to the Laspeyres and Fisher-Ideal
indexes.26
Results
The two series of price indexes described above are noted in the third
panel of tables 5.3 and 5.4. Limiting the price index to the rated epi-
sodes (Method 3, row 1), without reference to outcome, we observe
that the treatment price index falls from 100 in 1991 to 95.0 (Laspeyres),
and 97.2 (Fisher-Ideal) in 1996. These declines look remarkably similar
to those recorded using Method 2b. Once the rated outcomes from the
expert panel are incorporated, however, a somewhat different pattern
emerges. For both the Laspeyres (table 5.3) and Fisher-Ideal (table 5.4)
indexes, prices show a decline to 92 in 1992, an increase back up to
about 100 in 1993, a small increase to 101 to 102 in 1994, a larger in-
crease to 108 in 1995, and then a decrease to about 103 to 104 in 1996.
Because we observed an increase in the quality of care over time, the
sharp increases in outcomes-adjusted prices in 1993 and 1995 are sur-
prising.
In considering this surprising increase, we note that during the 1991
through 1996 period, increased levels of management have been exer-
cised over the mental health benefit. One implication of this trend is
that the patient population being treated may have been changing
(along with the mix of treatment bundles), thereby affecting both ex-
pected outcome and cost. Because our expected outcomes are assigned
based on both treatment and patient type, changes in the mix of pa-
tients will affect the price per remission. For example, the panel rated
patients with comorbid substance abuse to have lower expected out-
comes than patients without comorbid substance abuse receiving the
same treatment. These changes in the patient mix over time in our sam-
ple are not incorporated in the Method 3 price index.Measuring Productivity in Mental Health Care 139
VIII.Method 4
To account for the effect of changing patient mix on computed price in-
dexes, we employ hedonic-like equations. In Method 4, we use regres-
sion analysis to account for varying patient characteristics when
calculating the price index.
We have specified and estimated several such models, based on data
from the 8,187 rated treatment episodes.27 We delineate eight patient
categories, depending on whether medical comorbidity is present;
whether male; if female, whether over age 50; and whether there is
comorbid substance abuse. We estimated hedonic equations for the
price per expected full remission. The left-hand variable is the natural
log of spending per episode of treatment. The right-hand variables in-
clude the probability of a full remission associated with the patient's
treatment and patient type, dummy variables for seven of eight patient
categories, and year dummies (1991 is excluded).28
As expected, variations in patient categories were found to have
significant and substantial effects on treatment costs. The coefficient on
remission probability is positive and highly significant. The resulting
price index is presented in the last row of table 5.3. The magnitude of
the reductions from 1991 to 1996 is 12.8 percent in price per remission,
with an AAGR of 2.7 percent. The 1991 to 1996 differences are
significantly different from zero at the (p < 0.05) level, although in
some cases the intervening year estimates are not very precise (p <
0.10). The differences between the hedonic and traditional price in-
dexes appear to result, therefore, from a changing and increasingly
complex mix of patients, along with changes in treatment bundles over
the six-year period.
It is important to note that the hedonic regressions suggest a rather
different set of price movements than the traditional price indexes. The
main reason for the difference is that variables describing the composi-
tion of cases are included in the hedonic regression but are not properly
controlled for in the traditional price index calculations. The mix of pa-
tients has been changing over time. To illustrate this point, consider de-
pressed patients with medical comorbidities. In 1991, about 13 percent
of episodes involved comorbid medical diagnoses, but by 1995 nearly
23 percent of episodes involved such conditions, and in 1996 this share
fell to 19 percent. Comorbidities are known to complicate treatment
and make it more costly. Thus, when the hedonic model controls for the140 Busch, Berndt, and Frank
changing patient composition of the treated population, as well as
changes in expected outcomes, the price indexes show declines in the
nominal price of an expected remission.
IX.Decomposing Price Index Discrepancies
The variations in procedures used in Method I through Method 4 to
construct price indexes for the treatment of depression are summarized
in table 5.1. The price indexes presented in tables 5.3 and 5.4 attempt to
incorporate several conceptual improvements suggested by econo-
mists concerning the measurement of medical care price changes. Dif-
ferences between these indexes and official government-produced
price indexes emerge from several sources. In this section, we evaluate
the relative importance of the sources of these discrepancies. We begin
with the two BLS-like price indexes constructed for discrete inputs for
the care of depression, presented in the top panels of tables 5.3 and 5.4.
These price indexes mimic methods used in the construction of official
price indexes but use as inputs prices and quantities from the Medstat
MarketScan data. We incrementally add improvements, assessing the
resulting change in the price index at each of three methodological
steps.
To construct a BLS-like health care PPI for the treatment of depres-
sion, we take a weighted average of the estimate of the price index for
antidepressant drugs and the estimate of the price index for physi-
cians' services. The relevant weights are derived from the 1991
MarketScan data as the share of total expenditures attributed to each of
these categories. The resulting weights are 9 percent and 91 percent for
antidepressants and physicians' services, respectively. We first combine
the two indexes calculated using the fixed quantity weight Laspeyres
formula using these relative weights. As indicated in line 1 of table 5.7,
combining these indexes indicates a positive AAGR of 2.6 percent in
the price of health care used for the treatment of depression.
We repeat this calculation using the same weighting scheme but
combine the two price indexes calculated using the Fisher-Ideal index
formula. These results are noted in line 2 of table 5.7. Comparing the
fixed weight index with an index that includes more recent data in the
calculation, we find the AAGR declines from 2.6 percent to 2.0 percent.
Compared to the Laspeyres formula, the Fisher-Ideal formula indicates
the same price increase for antidepressant drugs but a decline in the
AAGR by 28 percent for physicians' services. Therefore, the smallerMeasuring Productivity in Mental Health Care 141
Table 5.7
Summary of price index calculations, 1991-1 996
AAGR
BLS-like medical care PPI for depression
using MarketScan dataLaspeyres formula +2.6
BLS-like medical care PPI for depression
using MarketScan dataFisher-Ideal formula +2.0
Treatment-episode approach 0.7
Incorporating expected outcome of
treatments, adjusting for patient characteristics 2.7
Total bias due to methodology 5.3
price increase found when using the Fisher-Ideal indexes to compute
the BLS-like medical care PPI is due exclusively to more current
weights in the physicians' services index. The similarity of the antide-
pressant drug price index under the two formulas might suggest that
the changing mix of treatments over time within a class (e.g., from one
drug to another) is not important for the measurement of price
changes. Although not reported here, a closer look at the data underly-
ing these calculations indicates some trends. We note a change in the
mix of drugs provided over time and differences in price change
among the drugs. Some have very small increases or a constant price,
while others have quite large increases. Therefore, the absence of a dif-
ference in price change when using more current quantity weights is
not due to systematic similarities in pricing trends among the drugs.
While the index number formula had a rather small effect on the BLS-
like medical care PPI for depression, this does not suggest this is likely
to be the case for changes in the price of treatment for other diseases.
In the next step of our decomposition, we compare a discrete input
approach to an episode of treatment approach. This comparison yields
a much different view of price movements over the same time period.
Line 3 of table 5.7 presents the AAGR calculated using a treatment-epi-
sode approach. Note that variations in the expected outcome of treat-
ments are not yet incorporated in this calculation. The negative AAGR
of less than 1 percent indicates a slight decline in price over this time pe-
riod. The difference between line 2 and line 3 may reflect changes
across treatment classes (e.g., a move from outpatient services to drug
treatments). If goods or services that are substitutes are not in the same
BLS item strata, calculating price movement for item strata separately
will not capture substitution between the item strata. At least in the142 Busch, Berndt, and Frank
case of treatment for depression, this fact may play an important role in
price change, for there has been significant substitution away from psy-
chotherapy to drug treatments. A second potential explanation of the
difference in price movements found using the treatment episode as
the unit of analysis is a decline in the quantity of treatment inputs
within treatment episodes. In later years, patients may be receiving
fewer psychotherapy visits or days of drug treatment within an
episode.
In the final step indicated in line 4 of table 5.7, we present a price in-
dex that incorporates both changes in expected outcome and in patient
characteristics based on expected outcome measures from an expert
panel. This modification to the price index methodology further re-
duces the estimate of price changes, indicating a negctive AAGR of 2.7
percent over the 1991-1996 time period. This figure suggests that im-
provements in expected outcomes resulting from changes in treat-
ments prescribed over this time period had a significant effect on
productivity in delivering health care services to treat depression.
This decomposition analysis indicates that the discrepancies found
between our preferred methodology and the BLS methodology can be
attributed mainly to moving to a treatment-episode approach and to
failure to account for changes in expected outcome. This suggests, at
least in the case of treatment for depression, that recent modifications
to BLS methodology such as more frequent updating of weights and
the use of a geometric mean formula, which do not address these dis-
crepancies, will have little effect on more reliably measuring price
changes over time in treating depression.
Our analysis does not enable us to predict the result of the BLS'
changes for the reliability of measuring changes in the cost of treatment
for other diseases; these BLS changes may in fact be important in reli-
ably measuring price changes for the treatment of other diseases. Our
results also suggest that more research may be needed on the impact of
the classification of goods and services to item strata and on the type of
classification system that will best capture the full impact of substitu-
tion among treatment classes over time.
X.Conclusion
We found the construction of various price indexes for the treatment of
depression to be instructive and useful. Several general lessons emergeMeasuring Productivity in Mental Health Care 143
from this research. First, we found that moving to an episode-of-care
approach matters for the measurement of price changes. Conceptually
this step is important because it takes us closer to what patients are ac-
tually buying when they consume medical careepisodes of treatment
versus individual health care inputs. Second, we learned that starting
to incorporate at least some measure of outcomes is important. Includ-
ing outcomes also takes us closer to what individuals are actually buy-
ing when they purchase health care. Finally, if we contrast our
preferred price index to traditional medical care price indexes, we find
that prices decline and productivity increases, rather than the opposite.
However, constructing episode-based, outcome-adjusted price indexes
is an extraordinarily difficult and cumbersome task. For public policy
and evaluation purposes, construction of such indexes is very impor-
tant. However, it is not necessarily practical or sensible for the Bureau
of Labor Statistics to calculate such an index on a monthly basis. When
public policy analysts and researchers evaluate and interpret changes
over time in the National Health Accounts, it is important that they
bear in mind that expenditures are the product of price times quantity.
If price indexes fail to portray reliably the changing use of medical in-
puts to treat episodes of illness, and if outcomes variation and patient
complexity are not taken into account, it becomes difficult if not impos-
sible to identify the sources of expenditure changes. How frequently,
how detailed, and by whom such medical care price indexes should be
constructed is an issue meriting urgent attention.
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Kessler, Mcconagle, Zhao et al. (1994), p. 12.
Kendler, Walters, Neale et al. (1995).
Kessler, McGonagle, Swartz et al. (1993), P. 91.
See Busch, Frank, and Berndt (1996).
The Depression Guidelines Panel (1993) provides a summary and interpretation of the
evidence on this point.
See American Psychiatric Association (1993).
Keller et al. (2000).
Levit, Lazenby, Braden et al. (1998), and Ford and Ginsburg (1997).144 Busch, Berndt, and Frank
For further discussion, see Berndt, Cockburn, and Griliches (1996), Griliches and
Cockburn (1994), Kanoza (1996), and Kelly (1997).
All procedure codes comprising at least 1A of 1 percent of all such outpatient claims
were included.
See, for example, Diewert (1976, 1981).
For a more detailed explanation of these methods see Frank et al. 1998a and Frank
etal. 1998b.
We thank Marce!la-Horwitz Lennon, Howard Goldman, and Alyssa Busch for their
clinical expertise.
Medicode (1998).
For discussion of defining episodes of care, see Keeler et al. (1986) and Wingert et al.
(1995).
We count days without treatment only after the number of days of supply in a drug
prescription has been exhausted, thereby assuming full compliance with the daily recom-
mended dosage.
A significant portion of inpatient episodes have unspecified outpatient follow-up,
thereby limiting that avenue for identifying treatments.
For a discussion, see Mechanic (1989) and McGuire (1989).
These were brand name drugs Effexor and Serzone.
See Crown, Obenchain, Englehart et al. (1996) and Wilde and Benfield (1998) for evi-
dence on differential TCA-SSRI compliance among patients.
There is a large amount of literature on the cross-sectional variation in medical treat-
ments for other conditions and illnesses. See, for example, Phelps (1992) and Phelps and
Mooney (1993). On the effects of cost containment and risk-sharing on choice of treat-
ment, see Berndt, Frank, and McGuire (1997); Goldman, McCulloch, and Sturm (1998);
and Ma and McGuire (1998).
See also Frank et al. 1999.
See Normand, Frank and McGuire (1999).
Experts were directed: "Using your best clinical judgment, consider an average
group of 100 patients presenting with major depressive disorder with an entry HDRS
score of 22 in 1998 to an average specialty mental health or primary care physician. After
sixteen weeks of the indicated treatment, how many patients will most likely fall into
each of the following categories: depression-free, mildly depressed, moderately de-
pressed, or no change? When completing the survey, please keep in mind the impact of
compliance and the average circumstances of routine practice on symptom reductions."
This table is reproduced from Normand, Frank and McGuire (1999) and is based on a
slightly smaller sample of episodes.
For the results of additional price index calculations, see Berndt et al. (2000a).
For a discussion of index number and hedonic methods to control for quality in the
medical care context and elsewhere, see Cockburn and Anis (2001), Gilbert (1961, 1962),Measuring Productivity in Mental Health Care 145
Griliches (1962), and Reder (1969). Price indexes with heterogeneous purchasers are con-
sidered by Diewert (1981), Fisher and Griliches (1995), and Griliches and Cockburn
(1994).
28. Full regression results appear in Berndt et al. (2000a).
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